2024–2025
Fuent (Qurgen’s China subsidiary) has initiated its Phase I clinical trial in China following an IND approval by the Center for Drug Evaluation (CDE). The study is being conducted at the following clinical sites:
- Zhongshan Hospital of Fudan University;
- Peking University Cancer Hospital;
- Cancer Hospital of Chinese Academy of Medical Sciences;
- Jiangsu Provincial People’s Hospital;
- Zhejiang Cancer Hospital.